NRx Pharmaceuticals Subsidiary Selected by DARPA for Phase 2/3 Clinical Trial Contract Negotiation

NRx Pharmaceuticals, Inc. announced that its subsidiary, NRx Defense Systems (NRXD), has been selected by the Defense Advanced Research Projects Agency (DARPA) for contract negotiations regarding a potential award. The award would support a Phase 2/3 clinical trial titled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS). This trial aims to evaluate the efficacy of robotic-enabled Transcranial Magnetic Stimulation combined with NRX-101 (D-cycloserine/lurasidone) for the treatment of depression. NRX-101 has previously received Breakthrough Therapy Designation from the FDA. The study is planned to be conducted at Harvard McLean Hospital, HOPE Therapeutics clinics, and military facilities including Walter Reed National Military Medical Center. While the selection for negotiation is a significant milestone, the company noted that it does not yet constitute a formal notice of award or a commitment of funds, as final terms are still subject to negotiation. The trial is currently registered on clinicaltrials.gov under identifier NCT07227103.